Last Updated on September 7, 2022 by GlobeNewsWire
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will present at the following upcoming investor conferences in September.
Conference and presentation details are as follows:
H.C. Wainwright 24th Annual Global Investment Conference (September 12 – 14, 2022) Format: Presentation and one-on-one investor meetingsDate and Time: Sept. 13, 2022 from 1:30 – 2:00 p.m. ETWebcast: Link
Cantor Fitzgerald Cell & Genetics Medicines Conference (September 15, 2022) Format: Panel and one-on-one investor meetingsTitle: Late-Stage and Commercial Gene & Cell Therapy Warriors: How They Got to/Crossed the Finish LineDate and Time: Sept. 15, 2022 from 10:40 – 11:50 a.m. ET
Presentation links, if available, will be added to the events section of the Capricor website and archived for approximately 30 days following the presentation date.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes capable of delivering nucleic acids, including mRNA, as well as proteins to treat or prevent a variety of diseases. For more information, visit capricor.com, and follow the Company on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on March 11, 2022 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on August 12, 2022. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:Raquel ConaKCSA Strategic Communicationsrcona@kcsa.com212.896.1204
Capricor Investor Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com617.435.6602
Capricor Company Contact:AJ Bergmann, Chief Financial Officerabergmann@capricor.com310.358.3200